Pharmacology Books

Book SynopsisTable of Contents1. Introduction to modern concepts in pharmaceutical biotechnology and drug development 2. Pharmacokinetic and pharmacodynamics of biotechnology products 3. Role of biotechnology in amino acids modification 4. Role of biotechnology in nucleic acid modification 5. Monoclonal antibodies: Development, characterization and therapeutic application 6. Development of nanoparticles: recent developments and future prospects 7. Production of biopharmaceuticals from genetically modified organisms 8. Metabolomics as bioanalytical approach for pharmaceutical biotechnology in drug development 9. New biological targets for drug discovery and development 10. Signaling pathways of membrane-spanning receptors for drug discovery and development

Read more less

Book SynopsisTable of ContentsPreface Drug Dosage and Nomenclature SECTION 1 GENERAL PRINCIPLES 1. Principles of Pharmacology and Mechanisms of Drug Action 2. Pharmacokinetics 3. Drug Discovery, Safety and Efficacy 4. Neurotransmission and the Peripheral Autonomic Nervous System SECTION 2 THE CARDIOVASCULAR SYSTEM 5. Ischaemic Heart Disease 6. Systemic and Pulmonary Hypertension 7. Heart Failure and Shock 8. Cardiac Arrhythmias 9. Cerebrovascular Disease and Dementia 10. Peripheral Artery Disease 11. Haemostasis SECTION 3 THE RESPIRATORY SYSTEM 12. Asthma and Chronic Obstructive Pulmonary Disease 13. Respiratory Disorders: Cough, Respiratory Stimulants, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis and Neonatal Respiratory Distress Syndrome SECTION 4 THE RENAL SYSTEM 14. Diuretics 15. Disorders of Micturition 16. Erectile Dysfunction SECTION 5 THE NERVOUS SYSTEM 17. General Anaesthetics 18. Local Anaesthetics 19. Opioid Analgesics and the Management of Pain 20. Anxiety, Obsessive-Compulsive Disorder and Insomnia 21. Schizophrenia and Bipolar Disorder 22. Depression, Attention Deficit Hyperactivity Disorder and Narcolepsy 23. Seizures and Epilepsy 24. Extrapyramidal Movement Disorders and Spasticity 25. Other Neurological Disorders: Multiple Sclerosis, Motor Neuron Disease and Guillain-Barré Syndrome 26. Migraine and Other Headaches SECTION 6 THE MUSCULOSKELETAL SYSTEM 27. The Neuromuscular Junction and Neuromuscular Blockade 28. Myasthenia Gravis 29. Nonsteroidal Anti-inflammatory Drugs 30. Rheumatoid Arthritis, Other Inflammatory Arthritides and Osteoarthritis 31. Hyperuricaemia, Gout and Pseudogout SECTION 7 THE GASTROINTESTINAL SYSTEM 32. Nausea and Vomiting 33. Dyspepsia, Peptic Ulcer Disease and Gastrooesophageal Reflux Disease 34. Inflammatory Bowel Disease 35. Constipation, Diarrhoea and Irritable Bowel Syndrome 36. Liver Disease 37. Obesity SECTION 8 THE IMMUNE SYSTEM 38. The Immune Response and Immunosuppressant Drugs 39. Antihistamines and Allergic Disease SECTION 9 THE ENDOCRINE SYSTEM AND METABOLISM 40. Diabetes Mellitus 41. The Thyroid and Control of Metabolic Rate 42. Calcium Metabolism and Metabolic Bone Disease 43. Pituitary and Hypothalamic Hormones 44. Corticosteroids (Glucocorticoids and Mineralocorticoids) 45. Female Reproduction 46. Androgens, Antiandrogens and Anabolic Steroids 47. Anaemia and Haematopoietic Colony-Stimulating Factors 48. Lipid Disorders SECTION 10 THE SKIN AND EYES 49. Skin Disorders 50. The Eye SECTION 11 CHEMOTHERAPY 51. Drugs for Infections 52. Drugs for Cancer SECTION 12 GENERAL FEATURES, TOXICITY AND PRESCRIBING 53. Drug Toxicity and Overdose 54. Substance Abuse and Dependence 55. Prescribing, Adherence and Information About Medicines 56. Drug Therapy in Special Situations Index

Read more less

Book SynopsisTeaches students detailed lab procedures and skills using hands-on practice. Included are 34 labs that teach administrative and clinical procedures such as using pharmacy reference texts, filling prescriptions, compounding medications, and preparing sterile intravenous products.

Read more less

Book SynopsisHere is the fourth edition of Tyler''s Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies, providing essential botanical information as well as folkloric background of herbal remedies in a clear, accessible style. Unlike other herb books, this book gives you a serious evaluation of both the positive and negative features of the use of the most important herbs for therapeutic purposes. This new edition features additional scientific data on herbs that will enable you to make wise, informed choices about the benefits and risks of herbs currently on the market.Viewing herbs from a scientific standpoint, the authors assess herbs based on available scientific information and include the latest details on advocacy literature and the new regulatory environment. Each write-up includes descriptive information on the source of the plant, its traditional uses, and an evaluation of the relevant and current literature which helps support or disprove intended use of tTable of ContentsContentsPreface Preface to The New Honest Herbal (ital) Preface to The Honest Herbal (ital), Third Edition Preface to Tyler's Honest Herbal, (ital) Fourth Edition Pros and Cons Laws and Regulations I. Herbs and Related Remedies Alfalfa Aloe Angelica Apricot Pits (Laetrile) Arnica Barberry Bayberry Betony Black Cohosh Blue Cohosh Boneset Borage Bran Broom Buchu Burdock Butcher's-Broom Caffeine-Containing Plants Calamus Calendula Canaigre Capsicum Catnip Cat's Claw Celery Seed The Chamomiles and Yarrow Chaparral Chickweed Chicory Coltsfoot Comfrey Cranberry Cucurbita Damiana Dandelion Devil's Claw Dong Quai Echinacea Ephedra (Ma Huang) Evening Primrose Eyebright Fennel Fenugreek Feverfew Fo-Ti (He-Shou-Wu) Garcinia Garlic and Other Alliums Gentian Ginger Ginkgo Ginseng and Related Herb Goldenseal Gotu Kola Grape Seed Extract Hawthorn Hibiscus Honey Hops Horehound Horsetail Hydrangea Hyssop Jojoba Oil Juniper Kava Kelp Lettuce Opium Licorice Life Root Linden Flowers Lobelia Lovage Milk Thistle Mistletoe Mormon Tea Muira Puama Mullein Myrrh Nettle New Zealand Green-Lipped Mussel Pangamic Acid (“Vitamin B 15”) Papaya Parsley Passion Flower Pau d'Arco Pennyroyal Peppermint Pokeroot Pollen Propolis Pygeum Raspberry Red Bush Tea Red Clover Rose Hips Rosemary Royal Jelly Rue Sage St. John's Wort Sarsaparilla Sassafras Savory Saw Palmetto Schisandra Scullcap Senega Snakeroot Senna Spirulina Suma Tansy Tea Tree L-Tryptophan Uva Ursi Valerian Wild Yam Witch Hazel Wormwood Yellow Dock Yohimbe Yucca Summarized Evaluation of Herbal Remedies Summary Chart Index Reference Notes Included

Read more less

Book SynopsisSetting up a GXP environment where none existed previously is a very daunting task. Getting staff to write down what they do for every task is a correspondingly difficult and time-consuming exercise. Examining how to maintain quality control in clinical trial research, A Practical Guide to Quality Management in Clinical Trial Research provides a cornerstone of knowledge for establishing a quality system that complies with the relevant regulations. There are many books available that cover how to interpret regulations. Going a step or two further, this book provides practical advice that is useful on a daily basis.The book contains information for various standards including GLPs, GCPs, and GMPs. It gives detailed explanations of how to prepare, update, and maintain SOPs and includes advice on training and development of personnel. Drawing directly on his years of experience, the author delineates a from-the-trenches methodology that creates a value-added quality management system from a business perspective. He provides a solid foundation as well as tips and techniques for establishing a quality system that will comply with all the relevant regulations. The author's integrated approach and anecdotal style turns technically accurate information into easy reading. The book arms you with tools and concepts that you can use to go beyond regulatory compliance and move into the realm of business quality improvement.Trade Review"…provides the reader with a pragmatic approach to the principles governing accepted methodologies within the working environment and provides some useful examples of these interpretational differences across industry."-Quasar"…provides a solid foundation as well as tips and techniques for establishing a quality system that will comply with all the relevant regulations."--Anticancer ResearchTable of ContentsIn the Beginning There Was GLP. Before GCP. Training in the Regulated Environment. Computing in the Regulated Environment. QA Activity. Beyond Compliance. Business Improvement. A Summary. Appendix: Information Resources and Acronyms.

Read more less

Book Synopsis

Read more less

Book SynopsisThis Atlas of Dermatology has a unique clinical orientation with an emphasis on morphology. The disease entities are arranged according to the morphology of lesions to aid diagnosis. This pattern of placement is more useful for both teaching and learning and serves as an important aid in making a diagnosis being based on the way patients present themselves in out-patient departments. With key diagnostic clinical pointers generously illustrated to help the reader in diagnosing and excluding clinical differentials, this Atlas will serve as a helpful source for medical residents and practitioners specialising in Clinical Dermatology.Key Features An atlas and text covering skin, mucosa, hair and nail diseases in skin of color Emphasis on key diagnostic clinical pointers 3000+ clinical images--multiple images of a disease to cover the clinical spectrum Dedicated section on Regional Dermatology and Skin changes in systemic diseases Table of ContentsForeword by Debabrata Bandyopadhyay. Foreword by Eckart Haneke. Preface. Acknowledgements. Editors. Assistant editors. Contributors. INTRODUCTION TO CLINICAL DERMATOLOGY. Overview of skin lesions. APPROACH TO CLINICAL DIAGNOSIS. Hypopigmented and depigmented macules and patches: Localized. Hypopigmented and depigmented macules and patches: Generalized. Hyperpigmented macules and patches: Localized. Acquired facial melanosis. Hyperpigmented macules and patches: Generalized. Diffuse hyperpigmentation. Reticulate and mottled pigmentation. Papules: Localized. Facial papules. Papules: Generalized. Follicular papules. Plaques: Localized. Plaques: Generalized. Nodules: Localized. Nodules: Generalized. Tumors. Vesicobullous lesions: Localized. Vesicobullous lesions: Generalized. Pustules: Localized. Pustules: Generalized. Clinical approach to ulcers. Ulcer: Single or few. Leg ulcers. Ulcers: Multiple. Scales: Localized. Scales: Generalized. Atrophy. Purpura. Erythema: Localized. Erythema: Generalized. Telangiectasia. Cysts and pseudocysts. Draining sinuses and fistulas. Eschar. Cutaneous horn. REGIONAL DERMATOLOGY. Scalp. Periorbital area. Ears. Nose. Oral mucosa. Tongue. Axillae and groins. Umbilicus and periumbilical region. Palms and soles. Male genitalia. Female genitalia. Nipple areola complex. Scrotum. Seborrheic area. Intertriginous areas. Nails. SKIN IN SYSTEMIC DISEASES. Nutritional deficiency disorders. Endocrine disorders. Renal disorders. Autoimmune rheumatic diseases. Hereditary disorders of connective tissue. Hepatic diseases. Cardiovascular diseases. Neurocutaneous conditions. Psychocutaneous disorders. Dermatoses in HIV-infected persons. Internal malignancy. Nails in systemic disease. MISCELLANEOUS. Head and neck mass. Red face. Leonine facies. Linear lesions. Annular lesions. Alopecia. Hypertrichosis and hirsutism. Vascular lesions. Vasculitis. Neonatal dermatology. Geriatric dermatoses. Dermatoses of pregnancy. Cutaneous adverse drug reactions. Dermatitis artefacta, dermatitis neglecta, and terra firma-forme dermatosis. Pruritus SineMateria. Hyperhidrosis. Anhidrosis. Photosensitivity in children. Photosensitivity in adults. Maculopapular rash. Fever with rash in children. Index.

Read more less

Book SynopsisThis volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and photodynamic therapies. The preparation and mechanisms of molecular targeting of cancer are presented and the authors focus on a diverse audience including undergraduates and research students.Features Timely coverage of changes in process control technology for the phamaceutical industry, a dynamic area in terms of products and manufacturing processes Provides an update on the unique requirements of these industries and how they differ from others, for example the microelectronics or specialized chemicals industries Draws on the author''s vaTable of Contents History of Cancer Therapies Cancer and Carcinogens Causes of Death from Cancer Passive Targeting Cancer Active Targeting Strategies Conventional Cancer Therapies Oral Anticancer Therapies Parenteral Anticancer Therapies Advanced Cancer Therapies The Advent of Micro and Nano-spheres for Cancer Treatment The Emergence of Liposomes in Cancer Therapy Niosomes-Based Anticancer Therapies Solid Lipid Nanoparticles-Based Anticancer Therapies Mesoporous Nanoparticles-Based Anticancer Therapies Antibody-Based Cancer Therapies Aptamer-Based Anticancer Therapies Polyamidoamines-Based Anticancer Therapies Photodynamic Therapies for Cancer Treatment

Read more less

Book SynopsisMedical Affairs is one of the three strategic pillars of the pharmaceutical and MedTech industries, but while clear career paths exist for Commercial and Research and Development, there is no formal training structure for Medical Affairs professionals. Medical and scientific expertise is a prerequisite for entry into the function, and many people transitioning into Medical Affairs have advanced degrees such as PhD, MD, or PharmD. However, these clinical/scientific experts may not be especially well-versed in aspects of industry such as the drug development lifecycle, crossfunctional collaborations within industry, and digital tools that are transforming the ways Medical Affairs generates and disseminates knowledge. This primer for aspiring and early-career Medical Affairs professionals equips readers with the baseline skills and understanding to excel across roles.Features:Defines the purpose and value of Medical Affairs and provides clear career Table of ContentsSECTION 1: MEDICAL AFFAIRS IN THE PHARMACEUTICAL AND MEDTECH INDUSTRIES Chapter 1 What Is Medical Affairs? Chapter 2 Groups and Structure of Medical Affairs Chapter 3 Medical Affairs Collaborations Across the Drug/Device Development Lifecycle Chapter 4 Measuring the Impact of Medical Affairs Chapter 5 Medical Affairs Careers SECTION 2: THE PRACTICE OF MEDICAL AFFAIRS Chapter 6 Medical Strategy and Launch Excellence Chapter 7 Evidence Generation and Real-World Evidence Chapter 8 Medical Communications Chapter 9 External Education Chapter 10 Field Medical Chapter 11 Insights Chapter 12 Medical Information Chapter 13 Patient Centricity Chapter 14 Medical Operations Chapter 15 Digital Strategy Chapter 16 Compliance Chapter 17 Rare Disease and Gene Therapy Chapter 18 Medical Affairs in MedTech

Read more less

Book SynopsisStahl''s Illustrated Sleep and Wake Disorders is a concise and highly illustrated guide to the environmental, neurobiological and genetic factors that influence sleep and wakefulness, with evidence-based guidance for the accurate diagnosis and optimal treatment of various sleep/wake disorders. All of the titles in the Stahl''s Illustrated series are designed to be fun. Concepts are illustrated by full-color images that will be familiar to all readers of Stahl''s Essential Psychopharmacology and The Prescriber''s Guide. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Within each book, each chapter builds on previous chapters, synthesizing information from basic biology and diagnostics to building treatment plans and dealing with complications and comorbidities.Table of Contents1. Neurobiology and genetics of sleep/wake disorders; 2. Assessment of sleep/wake disorders; 3. Treatment of sleep/wake disorders.

Read more less

Book SynopsisTable of ContentsPreface vi Contributors vii Part 1 Principles of clinical pharmacology 1 Pharmacodynamics and pharmacokinetics 3 2 Clinical trials and drug development 29 3 Pharmacoeconomics: the economic evaluation of new drugs 35 4 Practical prescribing 42 Part 2 Aspects of prescribing 5 Gastrointestinal system 51 6 Cardiovascular system: Management of coronary artery disease and its complications 63 7 Respiratory system 102 8 Nervous system 113 9 Infection 142 10 Drugs and endocrine disease 175 11 Genitourinary system 196 12 Malignant disease 211 13 Drugs and the blood 221 14 Musculoskeletal system 236 15 Immunopharmacology 242 16 Travel medicine 255 17 Analgesia and anaesthesia 266 18 Poisoning and drug overdose 281 Index 295

Read more less

Book SynopsisWith contributions by international experts in academia, chemical manufacturing, government research laboratories, regulatory agencies, and private consulting, this guide explores the potentially damaging influence of environmental agents on the endocrine system. It examines endocrine toxicology's increased importance in environmental safety issues due to legislative directives established over the past ten years.Covering all principal areas of EPA concern, Endocrine Toxicology, Third Edition provides: putative endocrine disruptors and mechanisms of endocrine toxicity the history and status of the regulatory process mechanisms of toxic effects in various hormonal systems comparisons of the endocrine responses in humans, livestock, and wildlife testing methods in mammalian, fish, avian, and amphibian models valuable insight into the approaches of various personnel in the field, iTrade Review "This is an excellent review of the effects of toxic substances on endocrine axes in both humans and wildlife.... The ambitious goals of covering the expanse of molecular toxicology and regulatory action are met by the book's diverse chapters......Because of the array of authors, the book serves as an excellent introduction to many areas related to endocrine toxicology....... The book does an excellent job of covering the topics in endocrine disruption that have become increasingly relevant over the last three decades. The classic mechanisms of endocrine disruption, namely alterations in estrogen and androgen signaling, are covered in two excellent chapters....As a whole, this book offers an excellent review of the effects of toxins on endocrine physiology with a particular strength in its coverage of government programs for monitoring these effects and the subsequent implications for regulatory policy. Because of the burgeoning knowledge in this area, this update is certainly appreciated, and subsequent editions will be welcome as our knowledge of endocrine disruption expands to other areas of endocrine physiology." Weighted Numerical Score: 94 - 4 Stars! [DOODY'S NOTES] [REVIEWER'S EXPERT OPINION]Robert Michael Sargis, M.D., Ph.D.(University of Chicago Medical Center) Table of ContentsRegulation of Endocrine Disruptive Chemicals in the United States. Pursuit of Endocrine Disruptors in Europe - the OECD Component. Impact of Endocrine Disruptor Policies and Regulations. The Hypothalamic-Pituitary-Gonadal Axis in Teleost Fish. The Hypothalamic-Pituitary-Gonadal Axis in Anuran Amphibians. The Hypothalamic-Pituitary-Gonadal Axis in Birds. The Hypothalamic-Pituitary-Gonadal Axis in Mammals. Comparing and Contrasting the Hypothalamic-Pituitary-Gonadal Axis in Different Vertebrate Classes. Male Reproductive Endpoints and the Rodent Hershberger Assay. Review of Bisphenol A by the National Toxicology Program. Pubertal Screening Assays in Rodents. Endocrine Disruption at Neuroendocrine and Neurotransmitter Sites. Endocrine Disruptor Interaction with Estrogen Receptors. Analysis of Endocrine Disruptors with Estrogen Reporter Systems. Time Dependent Embryotoxicity of the Endogenous Luteolysin, Prostaglandin F2alpha, in Ruminants. Actions of Endocrine Disruptors on the Thyroid Axis. Endocrine Disruption of Hormone Storage and Transport. Metal Toxicity in Mammalian Reproduction. Structure-Activity Modeling of Endocrine Disruptors. Overview of Endocrine Disruptor Ecotoxicity in Wildlife. Overview of USEPA Tests with Aquatic Vertebrates for Detecting and Assessing Endocrine Disrupting Chemicals. Biological Activity of Endocrine Disruptors in Aquatic Systems. Impact of Endocrine Disruptors on the Water Industry.

Read more less

Book SynopsisTerence Young exposes the pharmaceutical industry secrets and cultural myths that thwart our safe use of prescription drugs. Everyone should read it before their next visit to a doctor. DR. NANCY OLIVIERI, MD, physician and professor When it comes to drug safety, Big Pharma holds all the power, and it's time for patients to take it back.Tens of millions of patients in North America take prescription drugs, but the safety of these drugs is often based on medical myths. We are led to believe that if a medication isn't safe, the government would never allow it on the market and that doctors would never prescribe a drug that isn't proven effective. Who controls these narratives? And do they always have the best interests of patients in mind?In an in-depth study of the enormous influence the pharmaceutical industry has over our health, drug safety advocate Terence Young explores how those with the most to gain financially aTrade ReviewTerence Young exposes the pharmaceutical industry secrets and cultural myths that thwart our safe use of prescription drugs.… Everyone should read it before their next visit to a doctor. * Dr. Nancy Olivieri, MD, physician and professor *It’s all right here. Everything you need to know about the harms of medications, the destructive business model of Big Pharma and how you can keep yourself and your loved ones safe. Read it. It could save your life. Don’t wait until after a tragedy to find these things out. * Johanna Trimble, Canadian Medication Appropriateness and Deprescribing Network *Table of ContentsContentsPreface 1Introduction: The Hidden Plague 3Part I: What Doctors Won’t Tell Us About Prescription Drugs 91 Forbidden Knowledge and the Four Truths 112 Pharma Gods: The Power and the Glory 273 Ten Rules to Survive a Visit to a Pharmacy 374 Debunking Our Medicine Myths 57Part II: The Wizards 715 How the Drug Business Really Works 736 How the Medical Wizards Seized Control of Our Healthand Won’t Let Go 877 Chaos Reigns with Drug Names 99Part III: The Hydra 1098 The Healers 1119 The Pharmapuppets 12510 The True Nature of Power 13911 How Big Pharma Broke Medicine 14712 The Search for Truth 157Part IV: A Chamber Of Horrors 17713 Dirty Tricks, Nasty Surprises, and Types of Torment 17914 Prescripticide 19315 Ugly Stuff with Children 219Part V: Fighting Back — The Empowered Patient 23916 How to Talk to a Doctor About Prescription Drugsand Use Them Safely 24117 A Call for Reform 259Acknowledgements 273Appendix: Organizations That Can Help with Psychiatric Drugs 277Glossary of Abbreviations and Terms 281Notes 291Index 343About the Author 365

Read more less

Book SynopsisPoisons are topics of multidisciplinary concern. The clinician and the pathologist are sensitive to instances of human poisoning. The laboratory researcher, whether pharmacologist, physiologist, or biochemist, is oriented toward molecular modes of poison action. Both clinician and researcher are eager to learn of poisons that can be used as therapeutic agents or methodological tools. This volume is an attempt to underscore the multidisciplinary charac ter of neuropoisons. Six poisons of animal origin which are receiving considerable clinical and research attention are discussed. Each poison is presented first as a clinical entity, then as a topic of investigative research, and finally as an agent useful to the study of nerve function. Because no single volume on neuropoisons can be exhaustive, an attempt at balance is offered as compensation. Two snake venoms, two marine poisons,Table of Contents1 Clinical Aspects of Elapid Bite.- I. Introduction.- II. Elapidae.- A. Classification.- B. Geographic Distribution.- C. Venom Toxicity.- D. Venom Yield.- E. Epidemiology.- III. Symptomatology of Elapid Bite.- A. General Characteristics.- B. Local Poisoning.- C. Systemic Poisoning.- IV. Treatment.- A. Indigenous and Chemical Treatment.- B. First Aid.- C. Antivenins.- D. Cryotherapy.- E. Tracheostomy and Artificial Respiration.- F. Antibiotics and Tetanus Antitoxin.- G. Corticosteroids, Antihistaminics, and Other Drugs.- H. Treatment of Ophthalmia.- V. References.- 2 Mode of Action of Cobra Venom and Its Purified Toxins.- I. Introduction.- II. Chemistry of Cobra Venom.- A. Neurotoxins.- B. Cardiotoxin, Cobramines, DLF, Toxin ?, and Cytotoxin.- C. Enzymes.- D. Nonproteins.- III. Pharmacological Actions of Cobra Venom.- A. Toxicity, Symptoms Produced in Animals, and Cause of Death.- B. Absorption, Distribution, and Fate.- C. Actions on Neuromuscular Junction, Skeletal Muscle, and Nerve.- D. Action on Smooth Muscle.- E. Action on Sympathetic Ganglionic Transmission.- F. Action on the Cardiovascular System.- G. Local Action.- H. Actions on the Central Nervous System.- I. Actions on Blood.- J. Biochemical Effects.- K. Cytotoxic Effects.- IV. Concluding Remarks.- V. References.- 3 Symptomatology of Experimental and Clinical Crotalid Envenomation.- I. The Rattlesnake.- II. Rattlesnake Venom Potency.- A. Mouse.- B. Dog.- C. Monkey.- D. Averaged Potency.- III. Physiological Effects of Venom.- A. Effects of Venom on Cortical Electrical Activity.- B. Effects of Venom on Plasma Factors.- C. Effects of Actual Snake Bite.- IV. Treatment of Snake Bite.- V. Concluding Remarks.- VI. References.- 4 The Mechanism of Snake Venom Actions—Rattlesnakes and Other Crotalids.- I. Introduction.- A. Snakes in Family Crotalidae.- B. Components of Snake Venoms.- II. Action of Snake Venoms.- A. Local Actions.- B. Systemic Action.- C. Autopharmacological Effects.- D. Lethal Action of Snake Venoms.- III. References.- 5 The Use of Snake Venoms as Pharmacological Tools in Studying Nerve Activity.- I. Introduction.- II. Development and Differentiation of the Nervous System.- III. Neuronal Degeneration and Demyelination.- A. Immunosympathectomy by Antibodies to Nerve Growth Factor.- B. Neuropathological Changes Induced by Venoms.- IV. Axonal Conduction.- A. Use of Venoms as ChemicarDissectors.- B. Effects of Cholinergic Agents on Axonal Conduction.- C. The Acetylcholine Receptor.- D. Hyperexcitability.- V. Membrane Permeability.- A. Increased Permeability Induced by Venoms.- B. Structural Alterations Associated with Increased Permeability.- VI. Phospholipid Function in Nerve.- A. Component of Venom Responsible for Effects on Axon.- B. Mechanism of Phospholipase A Effects on Conduction and Permeability.- C. Maintenance of Conduction and Permeability in Presence of Phospholipid Splitting.- VII. Neuronal Metabolism.- A. Function and Structure of Mitochondria.- B. Acetylcholine—Synthesis, Storage, Release, and Hydrolysis.- VIII. Conclusions.- IX. References.- 6 Fugu (PufFer-Fish) Poisoning and the Pharmacology of Crystalline Tetrodotoxin in Poisoning.- I. Introduction.- II. Actual Conditions and Statistical Survey of Fugu Poisoning.- A. Varieties of Fugu.- B. Localization.- C. Influence of Season.- D. Statistical Survey.- E. Differences between Fugu Poisoning and Ciguatera.- III. Clinical Symptoms and Treatment of Fugu Intoxication.- IV. Pharmacological Actions Underlying Clinical Symptons.- A. Emetic Action.- B. Circulation.- C. Respiration.- D. Excitable Cells.- E. Nonexcitable Cells.- F. Biochemical Aspects.- G. Relationship between Chemical Structure and Pharmacological Action.- H. Absorption, Distribution, and Excretion.- V. Legislative Control for Preventing Fugu Poisoning in Japan.- VI. Tested Clinical Use of Crystalline Tetrodotoxin.- VII. References.- 7 Paralytic Shellfish Poisoning and Saxitoxin.- I. Occurrence and Distribution of Paralytic Shellfish Poisoning.- II. Shellfish Poisoning as a Public Health Problem.- III. Detection of Shellfish Poisoning.- IV. Isolation and Characterization of Shellfish Poisons.- V. References.- 8 Mechanism of Action of Tetrodotoxin (TTX) and Saxitoxin (STX).- I. Introduction.- II. The Nature of the Nerve Impulse.- III. Cellular Actions of TTX and STX.- A. Peripheral Nerve.- B. Skeletal Muscle.- C. The Acetylcholine System.- D. Action of TTX and STX on Generator Potentials.- IV. Comparison of TTX and STX.- V. Mechanism of Action.- A. The Active Form of TTX and STX.- B. Structure-Activity Relationship.- C. Possible Mechanism of Interaction.- D. The Interaction of TTX and STX with Calcium.- E. Model Systems.- VI. Conclusion.- VII. References.- 9 Tetrodotoxin and Saxitoxin as Pharmacological Tools.- I. Introduction.- A. History.- B. Chemistry.- II. Cellular Effects.- A. Properties of Excitable Membranes.- B. Actions of Toxins.- III. Pharmacological Uses.- A. The Early Transient Channel.- B. Synaptic Transmission.- C. Central Nervous System.- D. Generator Potentials.- E. Action Potentials Not Dependent on Sodium Ions.- F. General.- IV. Conclusion.- V. References.- 10 The Clinical Effects of Tetanus.- I. Tetanus: The World Problem.- II. Clinical Features.- III. The Natural History of Tetanus.- IV. Complications.- V. Causes of Death.- VI. Treatment.- A. Conservative Management.- B. Tracheostomy.- C. Intermittent Positive-Pressure Respiration.- VII. Prevention of Tetanus.- VIII. References.- 11 Biochemical and Physiological Aspects of Tetanus Intoxication.- I. Introduction.- II. The Toxin.- A. Components of Culture Filtrates.- B. Purification of Tetanus Toxin.- C. Molecular Weight of Tetanus Toxin.- D. The Relationship Between Dose and Response in Tetanus Intoxication.- III. Biochemical Mechanisms Involved in Tetanus Intoxication.- A. General Considerations.- B. Direct Action of Tetanus Toxin on Skeletal Muscle.- IV. Effect of Environmental Temperature on Tetanus Intoxication.- A. Activation Energy for the Process.- V. Binding of Tetanus Toxin.- A. Rate of Binding of Tetanus Toxin In Vivo.- VI. Physiology of Tetanus Intoxication.- A. Effects of Tetanus Toxin on Neuromuscular Junctions.- B. Effects of Tetanus Toxin on the Physiology of Skeletal Muscle and the Problem of Local Tetanus.- C. Dual Target Sites of Toxin Action: The Central Nervous System and the Skeletal Muscle.- VII. Summary.- VIII. References.- 12 Tetanus Toxin as a Neuropharmacological Tool.- I. Introduction.- II. Techniques of Administration.- III. Tetanus Toxin and Central Inhibition.- A. Spinal Cord.- B. Cerebral Cortex.- IV. Tetanus Toxin and Cholinergic Transmission.- A. Sphincter Pupillae.- B. Peripheral Neuromuscular Junction.- C. Central Cholinergic Junction.- V. Mode of Action.- VI. Conclusion.- VII. References.- 13 The Clinical Aspects of Botulism.- I. History.- II. Botulism as a World Health Problem.- A. The Disease in Humans.- B. The Disease in Animals.- III. Epidemiologic Considerations.- IV. Pathogenesis.- V. Clinical Features of Botulism.- VI. Diagnosis.- A. Routine Laboratory Studies.- B. Electrocardiographic, Electroencephalographic, and Electromyographic Studies.- C. Specific Diagnosis.- D. Differential Diagnosis.- VII. Treatment.- VIII. Prognosis and Recovery.- IX. Remaining Problems.- X. References.- 14 The Neuroparalytic and Hemagglutinating Activities of Botulinum Toxin.- I. Introduction.- II. Characterization of the Botulinum Toxin Molecule.- A. Purification of Botulinum Toxin.- B. Attempts to Separate Neurotoxin and Hemagglutinin.- III. Botulinum Hemagglutinin.- IV. Target Organs of Botulinum Neurotoxin.- V. Mechanism of Neurotoxin Action.- A. Peripheral Cholinergic System.- B. Central Nervous System.- VI. Reactive Sites Involved in Neurotoxin Activity.- A. Free Amino Groups.- B. Fluorescence and Toxicity.- C. Tryptophan.- VII. Conclusion.- VIII. References.- 15 Botulinum Toxin as a Tool for Research on the Nervous System.- I. Introduction.- II. Neuromuscular Transmission.- III. Botulinum Toxin as a Pharmacological Tool.- A. Characteristics of an “Ideal Blocking Agent”.- B. Comparison of Botulinum Toxin with Ideal Model.- IV. The “Trophic” Effects of Nerves.- A. Scope and Definition of the Problem.- B. Motor Nerves and Skeletal Muscle.- C. Possible Trophic Mechanisms.- D. Red and White Muscle.- E. Other Trophic Neuromuscular Relationships.- F. Conclusions.- V. Botulinum Toxin and the Autonomic Nervous System.- A. Parasympathetic Nervous System.- B. Sympathetic Nervous System.- VI. Botulinum Toxin as a Marker of Cholinergic Synapses: A Possible Future Use.- VII. The Role of Movement in the Development of Joints: A Model System.- A. Soft-Tissue Ankylosis.- B. Abnormalities of Joint Cavities and Other Articular Structures.- VIII. References.- IX. Appendix.

Read more less

Book SynopsisThis new volume focuses on clinical biochemistry fundamentals, cell culture techniques, and drug discovery and development concepts. It deals with three different fields of clinical research: cell culture, clinical biochemistry, and drug discovery and development.The book introduces cell animal and bacterial culture techniques and their potential uses as well as cell culture techniques. The biochemistry aspect of the book covers the principles of clinical biochemistry and biochemical analysis, biochemical aids to clinical diagnosis, measurement, and quality control. The book also presents important concepts in cell membrane receptor signal transduction pathways as drug targets.The drug development focus of the book discusses the fundamentals of human disease and drug discovery. Various in silico, in vitro, and in vivo approaches for drug discovery are examined, along with a discussion on drug delivery carriers and clinical trials. Overall, the volume provides an overview of the journey from clinical fundamentals to clinical output.Table of Contents1. An Introduction to Cell Culture 2. Animal Cell Culture 3. Bacterial Cell Culture 4. Potential Use of Cell Cultures 5. Principles of Clinical Biochemistry and Biochemical Analysis 6. Biochemical Aids to Clinical Diagnosis 7. Clinical Measurements and Quality Control 8. Cell Membrane Receptor 9. Mechanisms of Signal Transduction 10. Human Disease Drug Therapy and Drug Discovery 11. Drug Development: In Silico, In Vivo and System Biology Approach 12. Drug Development: Drug Delivery Carriers and Clinical Trial 13. Role of Micro RNA in Prostate Cancer Therapy 14. Pathogenesis, Molecular Mechanisms of Progression, and Therapeutic Targets of Liver Fibrosis: An Update 15. Prostate Cancer: Molecular Aspects, Biomarkers, and Chemo-Preventive Agents 16. Overview of Tuberculosis Biomarkers: An Update

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThis publication is based on peer-reviewed manuscripts from the 2019 Conference on Drug Design & Discovery Technologies (CDDT) held at Ramaiah University of Applied Sciences, India. Providing a wide range of up to date topics on the latest advancements in drug design and discovery technologies, this book ensures the reader receives a good understanding of the scope of the field. Aimed at scientists, students, regulators, academics and consultants throughout the world, this book is an ideal resource for anyone interested in the state of the art in drug design and discovery.Table of ContentsPart 1: Structure Based Drug Design Approach; MOLECULAR DYNAMICS SIMULATIONS ON BACILLUS SUBTILIS EngA – FOR EXPLORING NUCLEOTIDE DEPENDENT CONFORMATIONS; ERRORS MADE IN AB INITIO+ HOMOLOGY-BASED PROTEIN STRUCTURE PREDICTION TOOLS ARISE DUE TO LACK OF CONSIDERATION OF IMPACT FORCES; PARADIGM SHIFT IN RESEARCH FOCUS: COMPUTATIONAL SOFTWARES IN CANCER BIOLOGY; VIRTUAL SCREENING OF BIO-ACTIVE COMPOUNDS AS AN INHIBITOR OF C-FLIP PROTEIN FOR CANCER TREATMENT; FRAGMENT-BASED DESIGN OF NOVEL INHIBITORS OF HPV 16 E6 ONCOPROTEIN: MOLECULAR DOCKING, MOLECULAR DYNAMICS SIMULATION AND IN SILICO ADME ANALYSIS; DESIGN AND SYNTHESIS OF NOVEL POLY ADP-RIBOSE POLYMERASE 1 (PARP1) INHIBITORS FOR THE TREATMENT OF SOLID TUMORS; IN SILICO EVALUATION OF THE ROLE OF PHYTOCHEMICALS IN ALZHEIMER’S DISEASE THROUGH WNT SIGNALING MODULATION; IDENTIFICATION OF POTENTIAL VEGFR2 INHIBITORS EMPLOYING E-PHARMACOPHORE MODEL, VIRTUAL SCREENING, MOLECULAR DYNAMIC SIMULATION AND ADME ANALYSIS; DEVELOPMENT OF NEW NEPRILYSIN INHIBITOR AS A MODULATOR OF CHRONIC KIDNEY AND HEART DISEASE USING IN SILICO DRUG REPURPOSING APPROACH; ANTICANCER POTENTIAL OF PHYTOCONSTITUENTS MODULATING NA/ K ATPASE PUMP; A NOVEL REPURPOSING STRATEGY; IN SILICO HIT IDENTIFICATION, DRUG REPURPOSING, PHARMACOKINETIC AND TOXICITY PREDICTION OF c-MET KINASE INHIBITORS FOR CANCER THERAPY; DESIGN OF POTENT TELOMERASE INHIBITORS USING STRUCTURE BASED APPROACHES; MOLECULAR DOCKING BASED SCREENING OF “NITROGEN CONTAINING BISPHOSPHONATE CONJUGATE WITH HYDROXYAPETITE” ACTIVE CONSTITUENTS TOWARDS MELVONATE PATHWAY IN FINDING POTENT INHIBITORS FOR ANTI-OSTEOPOROTIC ACTIVITY; ZANAPEZIL, A POTENTIAL REPURPOSABLE DRUG AGAINST HUNTINGTON DISEASE: AN IN SILICO FORECAST; DRUG REPURPOSING FOR HEPATOCELLULAR CARCINOMA VIA VIRTUAL SCREENING INTEGRATED WITH BIOINFORMATICS ANALYSIS; AN IN SILICO TARGET SPECIFIC DRUG REPURPOSING APPROACH FOR MULTIPLE SCLEROSIS; Part 2: Structure Based Drug Design and Biological Evaluation; DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-PHENYLISOXAZOLO[5,4-D]PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS.; QSAR AND DOCKING STUDIES ON TRIAZOLE BENZENE SULFONAMIDES WITH HUMAN CARBONIC ANHYDRASE IX INHIBITORY ACTIVITY; DESIGN AND SYNTHESIS OF SOME NOVEL ERLOTINIB DERIVATIVES AS POTENTIAL EGFR KINASE INHIBITORS; DESIGN, SYNTHESIS AND CHARACTERIZATION OF NOVEL SERIES OF 1,3-THIAZOLE CONTAINING HETEROCYCLES AS INHIBITORS OF DHFR FOR USE AS ANTICANCER AGENTS; IN SILICO AND IN VITRO STUDIES OF BENZOHYDRAZIDE ANALOGUES AS POTENT ANDROGEN RECEPTOR ANTAGONIST; DESIGN, MOLECULAR DOCKING, SYNTHESIS AND ANTI-FUNGAL ACTIVITY OF NOVEL BENZIMIDAZOLE DERIVATIVES; SYNTHESIS, ANTIOXIDANT ACTIVITY AND COMPUTATIONAL STUDIES OF 2-SUBSTITUTED-L-THIAPROLINES; DESIGN, SYNTHESIS, CHARACTERISATION AND ANTIFUNGAL ACTIVITY OF NOVEL PYRIMIDONE DERIVATIVES; Part 4: Chemical Synthesis and Biological Evaluation; MICROWAVE-ASSISTED SYNTHESIS OF 4-BENZYLIDENE-2-(2-FLUOROPHENYL) OXAZOL-5(4H)-ONE DERIVATIVES CATALYSED BY EGG SHELL POWDER AND EVALUATION OF THEIR ANTI-MICROBIAL ACTIVITY; SYNTHESIS OF OXAZOLOQUINOLONE DERIVATIVES AND EVALUATION OF THEIR POTENCY TO REACTIVATE RAT BRAIN ACETYLCHOLINESTERASE INHIBITED BY CHLORPYRIFOS; Part 5:

Read more less

Book SynopsisThis edited volume reports the latest developments in practical and selective reactions and methods involving carbenes and nitrenes and provides details of the structural diversity of heterocycles.

Read more less

Book SynopsisThis book sets out the unique and paradoxical position biomedical science finds itself in, in the early 21st (superscript st) century. Science has never been stronger in shaping the world we live in; progress in medical science during most of the last century has helped to transform health care and prolong our lives; almost daily advances in biological science promise hope for the future and yet medical science has been in serious decline for the past three decades.Biomedical Science in the 21st (superscript st) Century: Sunset or New Dawn? sets out the recent decline in the context of medical science's stunning past successes. Professor Sheridan discusses the failure to translate new discoveries in biological science into medical advances; the dramatic decline in research productivity in the pharmaceutical industry in the context of falling numbers of clinical scientists; the disruption of medical science during prolonged and repeated reforms of health care delivery; changing social and political attitudes towards health care and science; the loss of trust in big pharmaceutical companies and recent revelations of fraud in science. The book deals with the creative nature of original science, how it is driven by curiosity and self-motivation and how these can be stifled by pettifogging managerialism.The book presents a vision of what medical science can deliver during the coming half century and what is needed to overcome the present challenges. It questions the assumptions that big is best in the organisation of science and suggests a new model for drug development based on a restoration of trust and a more constructive relationship between regulators and industry.Table of ContentsThe Rise and Fall of Medical Science in the 20th Century; Advances in Medicine: How Are They Made?; The Impact of the Changing Social, Political and Economic Environment on Medical Science; Fraud in Biomedical Science; The Decline of Biomedical Science Despite Unprecedented Technological Advances: A 21st Century Paradox; Changes in Medical Professionalism in the 21st Century and Their Impact on Medical Science; The Global Demographic Challenge: The Role of Medical Science; Biomedical Science in Modern Economies: Innovation and Health; The Centrality of Medical Science in the 21st Century: Protecting Health and Meeting Future Economic Challenges.

Read more less

Book Synopsis

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisPrognosis is a core concept in psychiatry. This book is concerned with prediction of neuroleptic treatment outcome in schizophrenia from a conceptual and methodological point of view. Various aspects of the topic, such as definition and measurement of response, dimensions of treatment outcome, neuropsychological, neuropsychopharmacological and neurobiochemical predictors as well as the clinical application of neuroimaging methods and neurogenetics are treated by experts in the field. One aim of the book is to summarize the present state of the art in prediction research and thereby to provide a useful compendium. Moreover guidelines for future research strategies are formulated.Table of ContentsPrediction research of neuroleptic treatment outcome in schizophrenia — state of the art: 1978–1993.- Prediction research of outcome in neuroleptic treatment — definitions and concepts.- General aspects of predictor research in schizophrenia and depression.- Target dimensions in prediction of neuroleptic response: concepts and instruments.- Predictors of outcome in schizophrenia: the concept of time.- Sex differences in the prediction of neuroleptic response.- Neuroleptic-psychosocial interactions and prediction of outcome.- Pharmacokinetic aspects of neuroleptics and prediction of outcome.- Extrapyramidal side-effects and prediction of neuroleptic treatment response.- Subjective effects of neuroleptics predict compliance.- Neuropsychological prediction of treatment response and outcome in schizophrenia.- Neurochemical and neuroendocrine measures and prediction of outcome to neuroleptic therapy.- Prediction of clinical response to neuroleptics and positron emission tomography in schizophrenia..- Brain morphology and prediction of neuroleptic treatment response in schizophrenia.- Prediction of neuroleptic response: genetic strategies.- Design, methodological and statistical issues in prediction research of neuroleptic response.- Panel Discussions.- Prediction research in neuroleptic therapy — future directions.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisComputational Drug Discovery A comprehensive resource that explains a wide array of computational technologies and methods driving innovation in drug discovery Computational Drug Discovery: Methods and Applications (2 volume set) covers a wide range of cutting-edge computational technologies and computational chemistry methods that are transforming drug discovery. The book delves into recent advances, particularly focusing on artificial intelligence (AI) and its application for protein structure prediction, AI-enabled virtual screening, and generative modeling for compound design. Additionally, it covers key technological advancements in computing such as quantum and cloud computing that are driving innovations in drug discovery. Furthermore, dedicated chapters that addresses the recent trends in the field of computer aided drug design, including ultra-large-scale virtual screening for hit identification, computational strategies for designing new therapeutic modalities like PROTACs and covalent inhibitors that target residues beyond cysteine are also presented. To offer the most up-to-date information on computational methods utilized in Computational Drug Discovery, it covers chapters highlighting the use of molecular dynamics and other related methods, application of QM and QM/MM methods in computational drug design, and techniques for navigating and visualizing the chemical space, as well as leveraging big data to drive drug discovery efforts. The book is thoughtfully organized into eight thematic sections, each focusing on a specific computational method or technology applied to drug discovery. Authored by renowned experts from academia, pharmaceutical industry, and major drug discovery software providers, it offers an overview of the latest advances in computational drug discovery. Key topics covered in the book include: Application of molecular dynamics simulations and related approaches in drug discovery The application of QM, hybrid approaches such as QM/MM, and fragment molecular orbital framework for understanding protein-ligand interactions Adoption of artificial intelligence in pre-clinical drug discovery, encompassing protein structure prediction, generative modeling for de novo design, and virtual screening. Techniques for navigating and visualizing the chemical space, along with harnessing big data to drive drug discovery efforts. Methods for performing ultra-large-scale virtual screening for hit identification. Computational strategies for designing new therapeutic models, including PROTACs and molecular glues. In silico ADMET approaches for predicting a variety of pharmacokinetic and physicochemical endpoints. The role of computing technologies like quantum computing and cloud computing in accelerating drug discovery This book will provide readers an overview of the latest advancements in Computational Drug Discovery and serve as a valuable resource for professionals engaged in drug discovery.Table of ContentsVolume 1 Preface xv Acknowledgments xix About the Editors xxi Part I Molecular Dynamics and Related Methods in Drug Discovery 1 1 Binding Free Energy Calculations in Drug Discovery 3Anitade Ruiter and Chris Oostenbrink 2 Gaussian Accelerated Molecular Dynamics in Drug Discovery 21Hung N. Do, Jinan Wang, Keya Joshi, Kushal Koirala, and Yinglong Miao 3 MD Simulations for Drug-Target(Un)binding Kinetics 45Steffen Wolf 4 Solvation Thermodynamics and its Applications in Drug Discovery 65Kuzhanthaivelan Saravanan and Ramesh K. Sistla 5 Site-Identification by Ligand Competitive Saturation as a Paradigm of Co-solvent MD Methods 83Asuka A. Orr and Alexander D. MacKerell Jr. Part II Quantum Mechanics Application for Drug Discovery 119 6 QM/MM for Structure-Based Drug Design: Techniques and Applications 121Marc W. van der Kamp and Jaida Begum 7 Recent Advances in Practical Quantum Mechanics and Mixed-QM/MM-Driven X-Ray Crystallography and Cryogenic Electron Microscopy (Cryo-EM) and Their Impact on Structure-Based Drug Discovery 157Oleg Borbulevych and Lance M. Westerhoff 8 Quantum-Chemical Analyses of Interactions for Biochemical Applications 183Dmitri G. Fedorov Part III Artificial Intelligence in Pre-clinical Drug Discovery 211 9 The Role of Computer-Aided Drug Design in Drug Discovery 213Stormvander Voort, Andreas Bender, and Bart A. Westerman 10 AI-Based Protein Structure Predictions and Their Implications in Drug Discovery 227Tahsin F. Kellici, Dimitar Hristozov, and Inaki Morao 11 Deep Learning for the Structure-Based Binding Free Energy Prediction of Small Molecule Ligands 255Venkatesh Mysore, Nilkanth Patel, and Adegoke Ojewole 12 Using Artificial Intelligence for de novo Drug Design and Retrosynthesis 275Rohit Arora, Nicolas Brosse, Clarisse Descamps, Nicolas Devaux, Nicolas Do Huu, Philippe Gendreau, Yann Gaston-Mathé, Maud Parrot, Quentin Perron, and Hamza Tajmouati 13 Reliability and Applicability Assessment for Machine Learning Models 299Fabio Urbina and Sean Ekins Volume 2 Preface xv Acknowledgments xix About the Editors xxi Part IV Chemical Space and Knowledge-Based Drug Discovery 315 14 Enumerable Libraries and Accessible Chemical Space in Drug Discovery 317Tim Knehans, Nicholas A. Boyles, and Pieter H. Bos 15 Navigating Chemical Space 337Akos Tarcsay, András Volford, Jonathan Buttrick, Jan-Constantin Christopherson, Máte Erdos, and Zoltán B. Szabó 16 Visualization, Exploration, and Screening of Chemical Space in Drug Discovery 365José J. Naveja, Fernanda I. Saldívar-González, Diana L. Prado-Romero, Angel J.Ruiz-Moreno, Marco Velasco-Velázquez, Ramón Alain Miranda-Quintana, and José L. Medina-Franco 17 SAR Knowledge Bases for Driving Drug Discovery 395Nishanth Kandepedu, Anil Kumar Manchala, and Norman Azoulay 18 Cambridge Structural Database (CSD)–Drug Discovery Through Data Mining & Knowledge-Based Tools 419Francesca Stanzione, Rupesh Chikhale, and Laura Friggeri Part V Structure-Based Virtual Screening Using Docking 441 19 Structure-Based Ultra-Large Virtual Screenings 443Christoph Gorgulla 20 Community Benchmarking Exercises for Docking and Scoring 471Bharti Devi, Anurag TK Baidya, and Rajnish Kumar PartVI In Silico ADMET Modeling 495 21 Advances in the Application of In Silico ADMET Models–An Industry Perspective 497Wenyi Wang, Fjodor Melnikov, Joe Napoli, and Prashant Desai Part VII Computational Approaches for New Therapeutic Modalities 537 22 Modeling the Structures of Ternary Complexes Mediated by Molecular Glues 539Michael L. Drummond 23 Free Energy Calculations in Covalent Drug Design 561Levente M. Mihalovits, György G. Ferenczy, and György M. Keseru Part VIII Computing Technologies Driving Drug Discovery 579 24 Orion A Cloud-Native Molecular Design Platform 581Jesper Sorensen, Caitlin C. Bannan, Gaetano Calabrò, Varsha Jain, Grigory Ovanesyan, Addison Smith, She Zhang, Christopher I. Bayly, Tom A. Darden, Matthew T. Geballe, David N. LeBard, Mark McGann, Joseph B. Moon, Hari S. Muddana, Andrew Shewmaker, Jharrod LaFon, Robert W. Tolbert, A. Geoffrey Skillman, and Anthony Nicholls 25 Cloud-Native Rendering Platform and GPUs Aid Drug Discovery 617Mark Ross, Michael Drummond, Lance Westerhoff, Xavier Barbeu, Essam Metwally, Sasha Banks-Louie, Kevin Jorissen, Anup Ojah, and Ruzhu Chen 26 The Quantum Computing Paradigm 627Thomas Ehmer, Gopal Karemore, and Hans Melo Index 679

Read more less

Book SynopsisThis workbook in stereochemistry is designed for students, lecturers and scientists in chemistry, pharmacy, biology and medicine who deal with chiral chemical compounds and their properties. It serves as a supplement to textbooks and seminars and thus provides selected examples for students to practice the use of the conventions and terminology for the exact three-dimensional description of chemical compounds. It contains 191 problems with extended solutions. Trade ReviewThe late Edgar Heilbronner, one of the great physical and organic chemists of the 20th century, had a particularly effective lecture. He started it as follows: "You know pretty much everything I am going to say. So let us begin with the questions." And up on the screen flashed the first question. The lecture continued in the same vein; Heilbronner’s carefully structured answers to just the right questions led to a fascinating seminar, and a learning experience. I thought of Edgar Heilbronner’s lecture as I read the Hellwich and Siebert "Stereochemistry Workbook." In it are 191 graduated problems, along with succinct and clear solutions. One has to know a little stereochemical lore to begin with, for instance the priority rules of the CIP system. But otherwise everything is taught, in exemplary fashion, just through the progression of questions and answers. Complexities of naming coordination compounds, and dealing with chirality planes and axes are not avoided. The examples grow increasingly challenging. The success of this small volume lies in the fact it has a hidden narrative structure. Complexity is introduced in stages; solutions to the problems are attainable goals. One is drawn in, it is fun to go on. And the book is decorated with fascinating short stories of pharmaceutical design and utility. We have here a rare instance of a well-designed workbook that constructs a learning experience better than that found in most textbooks. What more would I want to see in it? The ordinary (of reasonable Lewis structures, normal bond lengths, moderate temperature [T less than ~100 °C]) which is the province of the beautiful compounds that are discussed in this book, needs to be defined. The ordinary is not diminished by what constrains it, for the fantastic variety the normal world generates suffices. But it is good to be aware of just what the assumptions are. Let me give an example. In one problem, a set of isomers of a bicyclic compound (cyclothiazide) is eliminated from discussion because a bridge can be formed only by cis fusion. In another example, two isomers of a [CoCl2(H2NNH2)(PPh3)2] complex are said to be not possible, those where the H2NNH2 would bridge trans-positions on the octahedral metal. Indeed, both statements make sense, but it would be interesting to mention why they are true (strain, the long N–N bond necessary). And how it is in the nature of chemists to subvert the impossible, and what ingenious molecules might do if there is no option but the energetically costly impossible. "Stereochemistry Workbook," one of the most effective pedagogical texts I’ve encountered, re-emphasizes the fundamental role of geometry in chemistry. Molecules have shapes. The logic of isomerism, in all its manifestations, the life-and-death-determining necessity of describing three-dimensional geometry, our representational struggles to do so – these define the beauty of chemistry. (Roald Hoffmann, Cornell University, Beilstein Journal of Organic Chemistry 2009, 5, No. 38)Table of ContentsQuestions.- Answers.

Read more less

Book Synopsis

Read more less

Book SynopsisThe present volume gives a comprehensive overview on the current state of basic and clinical research on Anxiety and Anxiolytic Drugs. Using newly developed methods and techniques researchers are now beginning to understand the molecular mechanisms of anxiety, anxiety disorders and their treatment. In parallel, new drug targets have been generated and the first clinical studies with new compounds have been started. In 20 chapters written by numerous experts in the field comprehensive information on all relevant topics is provided. Table of ContentsLearning and Memory.- Animal Models of Anxiety.- Genetic Alterations of the Murine Serotonergic Gene Pathway: The Neurodevelopmental Basis of Anxiety.- Mutagenesis and Knockout Models: Hypothalamic- Pituitary- Adrenocortical System.- Mutagenesis and Knockout Models: NK and Substance P.- Genetic Epidemiology of Anxiety Disorders.- Interactions Between Corticotropin-Releasing Hormone and Serotonin: Implications for the Aetiology and Treatment of Anxiety Disorders.- Anxiety Disorders: Noradrenergic Neurotransmission.- Pathophysiology and Pharmacology of GABAA Receptors.- Excitatory Amino Acid Neurotransmission.- Neurobiology and Treatment of Anxiety: Signal Transduction and Neuronal Plasticity.- Neuropeptides in Anxiety Modulation.-Neuroendocrine Aspects of PTSD.- Anxiety Disorders: Clinical Presentation and Epidemiology.- Transcultural Issues.- Challenge Studies in Anxiety Disorders.- Pharmacotherapy of Anxiety.- New Pharmacological Treatment Approaches for Anxiety.- Pharmaco-Genomics.- Pharmaco-Proteomics.

Read more less

Table of Contentsof U.S.-Japan Joint Meeting on Phase I and II Clinical Trials.- The New NCI Screen and Its Implications for Clinical Evaluation.- The National Cancer Institute’s Natural Products Antineoplastic Development Program.- Methodology of Phase I Study in Japan.- Methodology of Phase II Clinical Trial in Cancer.- Phase II Study of Antineoplastic Agents in Japan.- Clinical Strategy for Evaluation of Anthracycline Analogues.- Preliminary Clinical Study of Aclacinomycin A.- Preclinical and Clinical Studies on Chlorozotocin, a New Nitrosourea with Decreased Bone Marrow Toxicity.- Continuation of Phase II Study of 1-(4-Amino-2-Methylpyrimidine-5-yl)-Methyl-3-(2-Chloroethyl)-3-Nitrosourea Hydrochloride (ACNU).- Review of Experimental Studies on Nitrosourea Derivates in Japan.- The Clinical Evaluation of Analogues, IV. Nitrosoureas.- Review of a New Antimetabolic Agent, 1-Hexylcarbamoyl-5-Fluorouracil (HCFU).- Review of a New Antimetabolic Agent, 1,1-Bis(Tetrahydro-2-Furanyl)-5-Fluoro-2,4-Pyrimidinedione (FD-1).- Effect and Mode of Action of N4-Behenoyl-?-D-Arabinofuranosylcytosine.- Strategy for Evaluation of a New Antitumor Agent in the Treatment of Breast Cancer.- Current Status of Breast Cancer Chemotherapy in Japan.- Present Status of Lung Cancer Chemotherapy in Japan.- Clinical Strategies in the Chemotherapy of Gastrointestinal Cancer.- Clinical Evaluation Strategy in Specific Disease Types — Clinical Study of Gastrointestinal Cancer Chemotherapy in One Institute of Japan.- A Review of Therapeutic Strategies for Phase I-II Trials in Genitourinary Cancer.- Recent Results of Using a Sequential Combination of Bleomycin and Mitomycin C in the Treatment of Metastatic Cervical Cancer.- Pharmacologic and Clinical Studies of N4-Behenoyl-1-Beta-D-Arabinofuranosylcytosine.

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisMetabolic research and especially that which focuses on the monooxygenase cytochrome P450 system has gone through dramatic progressive changes within the last decade. Availability of highly sophisticated analytical techniques has contributed to increased molecular understanding of biotransformation pathways. Nowadays designer drugs are computer composable focussing on metabolic stability. The rapid development of recombinant enzymes has, in many cases, replaced the intensive work on P450 isolation from naturally occurring sources. Recombinant P450s can be expressed in cell lines and thus made available for reproducible and constant use addressig a large number of scientific questions. This book describes the present position of such research.Table of Contents1 Xenobiotic Metabolism: From Intact Biosystem to Single Enzymes.- 2 Regulation of Xenobiotic-Metabolizing Cytochromes P450.- 3 Cytochrome P450 in Human Drug Metabolism: How Much Is Predictable?.- 4 Metabolic Activation of Anticancer Oxazaphosphorines by Cytochrome P450s: Development of a Model for Cancer Gene Therapy.- 5 The Use of Bacteria for Cytochrome P450 Expression.- 6 Expression of Cytochromes P450 in Yeast: Practical Aspects.- 7 Human Cells as an Expression System for Cytochromes P450.- 8 Metabolic Reactions and Recombinant Isoenzymes of Cytochrome P450: Information Generated and Value for Pharmaceutical Development.- 9 The Importance of Cytochrome P450 3A Enzymes in Drug Metabolism.- 10 Strategies for Verifying the Involvement of Specific Cytochrome P450 Enzymes in Xenobiotic Metabolism.- 11 Regulation of Cytochromes P450 by Substrate Interactions.- 12 Strategies for the Use of Single Cytochrome P450 Enzymes in Drug Research and Future Prospects.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThe 8th International Congress of Biorheology was held at the Pacifico Yokohama, Japan, a brand new, versatile convention center for international meetings, from August 3 through 8, 1992. There were many plenary lectures and symposia, one of which was entitled "Mechanics of the Venous System." It was at this symposium that we, the editors of this monograph, each presented papers. We then moved to Gifu, Japan, for the Gifu Workshop on Veins and Vascular Capacitance. This was held on August 9, 1992, with the Second Department of Medicine, Gifu University School of Medicine, serving as the host. Nine papers were presented in the oral sessions and there were five poster presentations. This monograph, which is intended to provide a bird's­ eye view of recent trends in studies of the venous system, is an outgrowth of the Gifu Workshop. While it is not exactly the Proceedings ofthat workshop, materials in the monograph were developed from ideas presented there.

Read more less